The KRW 600 billion antithrombotic industry is showing high interests in rapid growth of new products

Antithrombotic products, which have been 3 years since their launch, are energizing its depressed market through their rapid growth.

Particularly, Cilostan (Korea United Pharm) and Brilinta (AstraZeneca) have become dark horses as increasing almost double in prescription expenses compared to the last year.

According to the industry on the 26^th, Cilostan CR, which is made up of Pletaal (Otsuka...